spacer
home > pmps > winter 2018 > the right excipient
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Right Excipient

The global empty hard capsules market is anticipated to increase at a compound annual growth rate of 7.2% and to reach $213 billion in revenues by 2022 (1). Over the past five years, about 12% of all prescription-based (Rx) and overthe- counter (OTC) pharmaceutical products were dosed with hard capsules, according to FDA documentation.

Despite being overlooked in the formulation of prescription drugs, the soft gels market is predicted to grow to $755 million by 2022 (2). This is mainly due to their popularity in the nutraceutical markets and added value in difficult Rx formulations, including very low-dose APIs (< 3mg), potent compounds, hormones and cytotoxic compounds (safe handling), oxygenlabile APIs, and, especially, poorly soluble or permeable APIs. As the market expands and new formulation technologies are adopted, selecting the right ingredient is essential to achieve optimum performance and functionality.

Choosing the Right Excipient

Favoured for its high functional capabilities, gelatine has been used in both hard and soft capsules in the pharma and nutraceutical industry for over 100 years. Capsule manufacturing started in 1834 thanks to gelatine, which has been the safe and only choice for decades. The first commercially feasible gelatine alternative entered the market in 2001: a soft gel shell alternative made of modified starches (hydroxypropyl starch) and carrageenans. Subsequently, hard gelatine capsule alternatives were commercialised, using hydroxypropyl methylcellulose (HPMC) as the main shell ingredient and carrageenans or gellan gum as gelling aids.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Bjorn Vergauwen is Principal Scientist at Rousselot. He currently coordinates R&D projects, aiming to unlock the unmet potential of gelatine. His main expertise relates to the biophysical and biochemical principles underpinning gelatine’s behaviour in food and pharma applications and to its use in dosage forms. Dr Vergauwen has a PhD in biochemistry from Ghent University, Belgium. Before joining Rousselot in 2014, he had several missions as Post-Doctoral Researcher at Ghent University where he conducted research in enzymology and structural biology for 17 years.
spacer
Dr Bjorn Vergauwen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain

E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to the pharmaceutical and chemical industry, announced the availability of the Faubel-Med® Label, a smart label for investigational medicinal products. The Med Label features E Ink’s low-voltage film technology, bringing display modules and new system designs to pharmaceutical packaging.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement